SAB Biotherapeutics (NASDAQ:SABS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The firm presently has a $2.25 price target on the stock.
According to Zacks, “SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D. “
Separately, Chardan Capital dropped their price objective on SAB Biotherapeutics from $10.00 to $7.00 in a research note on Friday, May 13th.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Penserra Capital Management LLC acquired a new position in SAB Biotherapeutics in the 4th quarter valued at approximately $27,000. JPMorgan Chase & Co. bought a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $30,000. Spectrum Management Group LLC acquired a new position in shares of SAB Biotherapeutics in the fourth quarter valued at $39,000. Wolverine Asset Management LLC bought a new position in SAB Biotherapeutics in the fourth quarter worth $51,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in SAB Biotherapeutics during the fourth quarter worth $79,000. Institutional investors own 7.25% of the company’s stock.
About SAB Biotherapeutics (Get Rating)
SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer.
- Get a free copy of the StockNews.com research report on SAB Biotherapeutics (SABS)
- There Are Cracks In The Paint At Sherwin-Williams
- American Well Corporation Stock May Well Be Bottoming
- 3 Outperforming Energy Stocks with More in the Tank
- Three Beaten Down Stocks The Insiders Are Buying
- Should Medtronic Make the Cut For Your Recovery Watchlist?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.